Rheumatoid arthritis (RA) is an inflammatory disease that can cause severe joint destruction and disability, with subsequent high morbidity and mortality. Disease-modifying antirheumatic drugs (DMARDs) are the cornerstones of RA treatment. They not only relieve joint pain, swelling, and stiffness but also slow the radiographic progression of disease. Over the last 10-15. years, a new class of disease-modifying medications, biologic agents, has been added to the armementarium of DMARDs, and they are highly effective. However, there remains considerable heterogeneity in patients' response to these agents. Pharmacogenetics may offer a reliable means of predicting an individual patient's response to a given DMARD prior to initiation of therapy. In this chapter, we review the current literature on the pharmacogenetics of traditional and biologic DMARDS in RA. Pharmacogenetics holds the promise of individualizing RA drug therapy.
|Title of host publication||Handbook of Pharmacogenomics and Stratified Medicine|
|Number of pages||29|
|State||Published - May 6 2014|
- Biologic DMARDS
- Non-biologic DMARDS
- Rheumatoid arthritis (RA)